The FDA ordered that the class of drugs known as TNF blockers carry a warning on the packaging that their use carries the risk of developing a potentially deadly fungal disease called histoplasmosis. [...]
|
|||||||
 |
Etanercept, marketed under the name Enbrel, is a drug that belongs to the class of drugs known as tumor necrosis factor (TNF)-alpha blocker. It is used primarily to treat rheumatoid arthritis, but has also been approved for use in treating polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. On May 1st, the U.S. [...] Treatments prescribed for treatment of rheumatoid arthritis in adults may not be well tolerated in children. Studies presented last month at the American College of Rheumatology (ACR) suggest that some of these drugs are appropriate for treating juvenile rheumatoid arthritis (JRA). Three studies were included in the report which included data on adalimumab (Humira), abatacept, [...] A recent study was conducted by Belgian researchers to determine the relationship between juvenile idiopathic arthritis (JIA) and craniofacial alterations. Their findings were published in the September, 2007 issue of the Journal of Rheumatology. They based their study on 100 patients with various subtypes of JIA. This included 12 with systemic arthritis, 25 with polyarthritis, 39 [...] A report published today by the Centers for Disease Control and Prevention estimates that 300,000 children in the U.S. suffer from some from of arthritis. Included in that estimate are some 50,000 to 100,000 that suffer from juvenile rheumatoid arthritis, a disease that can lead to permanent joint damage. This report, published in the December issue [...] |
  
|
|||||
|
Copyright © 2010 Current Arthritis News and Research - All Rights Reserved
|
|||||||
Recent Comments